Headline & intro
Whoop was once the discreet black band you noticed on the wrists of golfers and NBA stars. Now it’s a $10.1 billion company with sovereign wealth funds, global hospitals and Cristiano Ronaldo on the cap table. That jump in valuation is not about selling more straps. It’s about a bet that the next wave of healthcare will be built on continuous, consumer-grade biometric data — and that Whoop can own a crucial slice of that stack.
In this piece we’ll unpack what this funding really signals, why medical players are suddenly so interested, what it means for rivals like Apple and Oura, and how this could reshape digital health, including in Europe.
The news in brief
According to TechCrunch, fitness and health wearable maker Whoop has raised a $575 million Series G round at a valuation of roughly $10.1 billion, almost tripling its last reported valuation of $3.6 billion. The company has now collected about $900 million in funding since it was founded.
The round is led by Collaborative Fund and includes large institutional backers such as Mubadala Investment Company, Qatar Investment Authority, Macquarie Capital and several venture firms. Notably, medical device heavyweight Abbott and U.S. health system Mayo Clinic are investing, alongside a roster of star athletes and celebrities including Cristiano Ronaldo and LeBron James.
Whoop’s CEO told TechCrunch the company exited last year with a bookings run rate of about $1.1 billion, doubling year-on-year, and framed bookings as the key metric for a hardware-plus-subscription business. The fresh capital is earmarked for hiring, marketing, R&D and faster international expansion. While rival Oura is reportedly exploring an IPO, Whoop says only that it is doing the groundwork required to eventually operate as a public company.
Why this matters
A $10.1 billion valuation for a wristband company sounds absurd until you realise investors are not paying for plastic and sensors. They are paying for a long-term claim on streams of physiological data and the algorithms built on top.
Who benefits first? Obviously Whoop’s shareholders, but also Abbott and Mayo Clinic, who now gain privileged access to a real-time, longitudinal data source that traditional clinical trials rarely achieve. For Abbott in particular, this is a hedge against being disrupted by software-first players in cardiology, sleep and metabolic health.
The losers are any wearable players still stuck in the “steps and notifications” era. Mid-tier fitness trackers with no clear data strategy — or no credible path into reimbursable healthcare — will find it harder to raise serious money when investors can point to a $10B pure-play performance and health platform.
For consumers, the picture is mixed. On the plus side, more capital means better sensors, better sleep and strain models, and potentially earlier detection of problems from overtraining to atrial fibrillation. On the minus side, the incentive to monetise data — via insurers, employers or pharma — only grows as valuations climb.
Strategically, this round cements Whoop as a different animal from Apple Watch or Garmin. Apple sells a multipurpose device and layers health on top. Whoop sells health first, everything else second. That clarity of purpose is precisely what late-stage investors are betting on.
The bigger picture
This deal sits at the intersection of several powerful trends.
First, the consumerisation of healthcare. Over the last decade, we’ve watched blood oxygen readings, ECGs and fertility tracking move from clinics into people’s homes. Whoop goes further: it positions around continuous coaching rather than one-off measurements. This is much closer to where healthcare is heading — from episodic treatment to ongoing risk management.
Second, the hardware-as-subscription experiment. Peloton, Tonal and others showed that Wall Street loved recurring revenue — until it didn’t. Whoop’s bookings figure is an attempt to reassure investors that it understands the cash dynamics of shipping millions of devices while recognising revenue over months or years. The lesson from Peloton’s boom-and-bust is clear: if growth is fuelled purely by hardware sales, you are vulnerable. If you can prove long-lived subscriptions with low churn, you’re a software company with a sensor, not a bike manufacturer with an app.
Third, the data and AI race. Wearables are becoming AI training pipelines. Every night of sleep scored and every workout logged feeds models that can personalise recommendations, estimate injury risk or even flag depression and long Covid. The more users Whoop accumulates, the stronger its data moat becomes. This is why late-stage investors are comfortable paying software-like multiples for what looks like hardware: they’re betting the marginal value of the dataset grows faster than the cost of the devices.
Finally, there’s competition. Oura is reportedly lining up its own IPO. Apple is battling regulators while trying to add more medical features to the Watch. Google has largely absorbed Fitbit and is still working out how far it can push health tracking under regulatory scrutiny. Whoop’s raise is effectively a statement: it wants to be the independent, platform-agnostic performance layer in that ecosystem.
The European angle
For European users and companies, Whoop’s evolution from gadget to proto-medical platform raises both opportunities and hard questions.
On the one hand, Europe is fertile ground. Sports culture is strong, from cycling in France and Belgium to football across the continent. Health systems are straining under ageing populations and chronic disease. A continuous stream of validated physiological data could help shift care from hospitals to homes — something EU policymakers say they want.
On the other hand, Europe’s regulatory stack is about to get much tougher. Whoop’s algorithms that recommend training load or flag health risks will be evaluated under the EU AI Act. Any expansion into diagnostic or therapeutic use cases pushes the device towards the EU Medical Device Regulation (MDR) regime, which demands clinical evidence and robust post-market surveillance.
Then there’s GDPR. Whoop likes to market discretion — no screen, minimal notifications. But under European law, what matters is not how visible the device is, but what happens to the biometric data. Cross-border transfers to U.S. servers, secondary use of data for research or partnerships with insurers will all be under heavy scrutiny, especially in privacy-conscious markets like Germany.
Whoop will also face more local competition here than in the U.S. Withings in France, Polar in Finland and several German medtech firms are positioning themselves as privacy-friendly, clinically validated alternatives. If Whoop wants to convince European regulators and health systems, it will need more than celebrity investors — it will need clinical studies, transparent data practices and, ideally, EU-based data processing options.
Looking ahead
The obvious question is whether this round is the last stop before an IPO. The honest answer: not necessarily. At a $10B valuation, Whoop can afford to stay private longer, especially if public markets remain volatile. A more likely near-term path is aggressive scaling in healthcare and enterprise, using this war chest to secure hospital, insurer and employer deals that lock in recurring revenue.
Expect three things over the next 24–36 months.
First, a push for medical credibility. That means clinical trials with partners like Abbott and Mayo Clinic, regulatory filings in the U.S. and EU, and possibly specific features aimed at conditions such as sleep apnea, cardiac issues or overtraining syndromes.
Second, deeper integration into high-performance environments: professional teams, military units, corporate wellness programmes. This brings revenue but also ethical dilemmas: at what point does "performance optimisation" become surveillance of employees or athletes?
Third, more differentiation from mainstream smartwatches. Whoop will likely double down on battery life, comfort and analytics rather than adding screens or apps. It wants to be the always-on sensor that feeds insight into any ecosystem, not another mini-smartphone on your wrist.
For readers, the key signal to watch isn’t just whether Whoop files for an IPO. It’s how far the company is willing to go in monetising its data — and how regulators respond.
The bottom line
Whoop’s $10.1 billion valuation is less a fitness story and more a wager that continuous, consumer-generated health data will underpin the next decade of medicine. If Whoop uses this capital to earn real medical trust and respect European privacy norms, it could become a critical piece of global health infrastructure. If it chases growth by selling ever more intimate data to the highest bidder, regulators and users will eventually push back. The real question is simple: who do you want owning a live feed of your physiology?
